Press "Enter" to skip to content

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

The results showed the drug, Bavencio, in combination with, or as a follow-on treatment to, platinum-based chemotherapy could not achieve the primary goal of progression-fee survival in patients.

Original source:

Also Read:   Germany wards off US virus vaccine interest